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Protein translationAminoacyl-tRNA synthetases are central enzymes in protein translation, providing the charged tRNAs
needed for appropriate construction of peptide chains. These enzymes have long been pursued as drug
targets in bacteria and fungi, but the past decade has seen considerable research on aminoacyl-tRNA syn-
thetases in eukaryotic parasites. Existing inhibitors of bacterial tRNA synthetases have been adapted for
parasite use, novel inhibitors have been developed against parasite enzymes, and tRNA synthetases have
been identiﬁed as the targets for compounds in use or development as antiparasitic drugs. Crystal
structures have now been solved for many parasite tRNA synthetases, and opportunities for selective
inhibition are becoming apparent. For different biological reasons, tRNA synthetases appear to be
promising drug targets against parasites as diverse as Plasmodium (causative agent of malaria), Brugia
(causative agent of lymphatic ﬁlariasis), and Trypanosoma (causative agents of Chagas disease and human
African trypanosomiasis). Here we review recent developments in drug discovery and target character-
isation for parasite aminoacyl-tRNA synthetases.
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The prevalence and persistence of parasitic infections are both
remarkable and troubling phenomena. Approximately one billion
people harbour at least one worm infection (nematodes and platy-
helminths) (Lustigman et al., 2012) and many individuals are simul-
taneously infected with multiple parasites from distantly related
eukaryotic phyla (Fevre et al., 2008; Gething et al., 2011; Nacher,
2012). These parasites cause diseases that impose a serious burden
to the health and economic development of affected countries, and
are therefore the subject of many varied prevention and control
strategies. No human-licensed vaccine exists for any eukaryotic dis-
ease, therefore drugs are a major component of intervention against
most parasitic diseases (Prichard et al., 2012). Drug based strategies
include treatment of veriﬁed infections, mass drug administration to
presumptive infected communities or at risk individuals (e.g. preg-
nant mothers), and sporadic prophylaxis for individuals. In many
cases existing drug-based programs are at risk from parasites devel-
oping resistance, and therefore rendering ineffective our affordable
and effective drugs. Some antiparasitic drugs have already had their
effective usage severely restricted in regions due to the development
of widespread drug resistance (Baird, 2005; Croft and Olliaro, 2011).
The development of future control strategies is threatened by the
impending and inevitable emergence of resistance to additional
drugs (Geerts and Gryseels, 2000). To deal with existing and future
shortcomings of antiparasitic drugs, multiple classes of new drugs
are urgently needed for many parasitic diseases.
Parasites cause diverse types of disease, requiring drug treat-
ments that address varying causes of pathogenesis. Apicomplexan
parasites include Plasmodium spp., Toxoplasma gondii and Cryptos-
poridium. All parasites in this phylum are obligate intracellular par-
asites, but their host range and disease type varies immensely.
Plasmodium species cause generally acute disease through prolifer-
ation within and destruction of erythrocytes. Most existing anti-
malarial drugs work by killing this proliferative intra-erythrocytic
stage, though action against the parasite forms that initially infect
humans (sporozoites) and the forms that are transmitted to mos-
quitoes (gametocytes) is highly desirable in addition to disease
control purposes (Burrows et al., 2013). Toxoplasma gondii para-
sites infect many diverse animals and many cell types. In humans,
Toxoplasma is normally pathogenic only in immunocompromised
individuals or in the human foetus. Drugs are needed to arrest
the faster growing tachyzoite stages of Toxoplasma, as well as the
latent bradyzoite stages that form cysts in the brain and other or-
gans (Rodriguez and Szajnman, 2012). Cryptosporidium infects epi-
thelial cells of the intestine, causing potentially severe and chronic
diarrhea. As with Toxoplasma, the most severe Cryptosporidium
cases are in immunocompromised individuals, and the need for
drugs is more pressing for treatment of such cases (Rossignol,
2010).
Typanosomatid parasites also cause a broad spectrum of dis-
eases. Trypanosoma brucei, spread by the bite of the tsetse ﬂy,
causes human African trypanosomiasis, also known as sleeping
sickness. These parasites proliferate extra-cellularly in the blood-
stream and lymphatic system and later infect the central nervous
system (CNS) (Barrett et al., 2007). This disease is fatal within
months to years if not treated, andmost existing treatments are dif-
ﬁcult to administer, toxic or ineffective. New drugs must overcome
the additional challenge of crossing the blood brain barrier to treat
parasites in the CNS. Trypanosoma cruzi infections are the cause of
the chronic and potentially fatal Chagas disease. Existing drugs to
treat T. cruzi are ineffective if not administered early during infec-
tion and are highly toxic. Leishmania, the second medically impor-
tant genus of trypanosomatid parasites, includes species that also
cause a range of serious human diseases. In humans, Leishmaniaparasites invade and grow within phagocytic cells. As with other
trypanosomatid parasites, existing drugs are generally toxic, difﬁ-
cult to deliver and subject to parasite resistance (Stuart et al.,
2008). Although trypanosomatid parasites kill fewer people than
malaria, the lack of effective and safe drugs arguably makes discov-
ery of new drugs even more pressing for these parasites.
Three parasiteswhose anaerobicmetabolismdistinguishes them
from most other eukaryotes are the extracellular parasites Giardia,
Trichomonas, and Entamoeba. In these parasites the mainstays for
treatment are the nitroimidazole drugs, which are activated by
the parasites’ unusual pyruvate:ferredoxin oxidoreductase en-
zymes (Ali and Nozaki, 2007). In each of these parasites, resistance
to nitroimidazol is possible through altered metabolism and alter-
native drugs are scarce or ineffective (Upcroft and Upcroft, 2001).
The ﬁnal parasite discussed below in the context of tRNA syn-
thetase targets is the helminth parasite Brugia. Brugia malayi is a
nematode spread between humans by mosquitoes and is one of
several parasites to cause human ﬁlariasis. Lymphatic ﬁlariasis is
caused by immunological reaction to the adult worms and the
thousands of transmissive microﬁlaria they produce. Drug discov-
ery against nematodes introduces the added difﬁculty of selective
inhibition between the bilaterian animal parasites and their hosts,
although Brugia’s dependence on its bacterial Wolbachia symbiont
may offer other potential drug targets (Bandi et al., 2001).2. Protein translation as a drug target
One biological pathway that has been thoroughly validated as a
target for anti-infective compounds in a wide range of microbes is
the process of protein translation. Most antibiotics that target pro-
tein translation interact with microbial ribosomes themselves—
binding directly to the rRNA or ribosomal subunit proteins. How-
ever, additional molecules within the broader process of protein
translation can act as targets for drugs. One such target for existing
and future antimicrobial therapeutics is the aminoacyl-tRNA syn-
thetase (aaRS) family. This family of enzymes catalyses the attach-
ment of amino acids to their cognate tRNAs to produce the
aminoacyl tRNAs (also aa-tRNA or charged tRNA) that are the sub-
strates for translation (reviewed by Ibba and Soll, 2000). The aaRSs
enzymes are not only responsible for producing the raw materials
for translation, but also for ensuring the ﬁdelity of translation from
nucleic acid to amino acid information. Disruption of aaRSs there-
fore interrupts or poisons the process of protein translation. Com-
pounds that inhibit aaRSs have been successfully exploited, with at
least one antibacterial drug, mupirocin, currently in clinical use for
the topical treatment of Staphylococcus aureus, that acts through
the inhibition of the isoleucyl-tRNA synthetase (IleRS) of gram-po-
sitive bacteria (Nakama et al., 2001). The pursuit of diverse other
aminoacyl-tRNA synthetases has yielded speciﬁc aaRS inhibitors
(Rock et al., 2007), some of which are currently in clinical trials
as antimicrobials (de Jonge et al., 2006; Koon et al., 2011).
Besides the excellent precedence for druggability in bacteria,
there are several reasons to support protein translation in general,
and aaRSs speciﬁcally, as a useful antiparasitic target. First is the
dependence of many parasites on abundant protein translation in
fast growing cells. Because many parasites constitutively undergo
active and continuous proliferation they are heavily reliant on efﬁ-
cient protein translation and may be sensitive to disruptions to the
translation machinery. Other parasites pass through quiescent life-
stages with relatively little cellular proliferation—these stages
(such as the bradyzoite stages of Toxoplasma gondii) are likely to
have a reduced requirement for protein turnover and may be less
sensitive to translation inhibitors. Such stages present a general
problem for chemotherapy, though it is noteworthy that inhibition
Fig. 1. Schematic representation of an aminoacyl-tRNA synthetase. Various aaRS domains are illustrated: the editing domain (red); catalytic domain (cyan); anticodon-
binding domain (indigo); and parasite-speciﬁc domains (purple). Possible sites of interaction between aaRS and compound (with existing examples) are indicated by
numbers: editing site (1); active site (2); allosteric sites (3); parasite-speciﬁc domains (4); and anticodon-binding site (5). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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rifampicin, has been successfully exploited for slow-growing mi-
crobes such as latent stage Mycobacterium tuberculosis (Leung
et al., 2011). A second aspect of parasite protein translation that
renders it a plausible drug target is the immense evolutionary dis-
tance between this process in some parasites and human hosts.
Furthermore, several parasites have bacterial-like protein transla-
tion pathways that are not shared by humans. Apicomplexan par-
asites in particular, are dependent on their relict plastid
(apicoplast), which retains much of the cyanobacterial protein
translation apparatus of plastids’ ancestor (Jackson et al., 2011).
Trypanosomatid parasites are highly dependent on protein transla-
tion in their unusual kinetoplastid mitochondrion, and the protein
translation therein differs in several aspects from the translation
found in human mitochondria or cytosol (Schneider, 2001; Nie-
mann et al., 2011). These examples highlight the presence of aaRSs
in multiple organelles, all of which may be considered when con-
templating drug targets.
A number of recent reviews have detailed drug discovery and
development against bacterial and fungal aaRSs (Kim et al., 2003;
Ochsner et al., 2007; Vondenhoff and Van Aerschot, 2011; Lv and
Zhu, 2012). In this review we discuss prospects for drug develop-
ment against the aaRSs of eukaryotic parasites, including apicom-
plexan, trypanosomatid, and metamonad protists as well as
parasitic worms.3. Aminoacyl-tRNA synthetases as drug targets
Before considering speciﬁc parasite targets, let us brieﬂy con-
sider what types of activities might be inhibited when focusing
on aaRSs. Aminoacyl-tRNA synthetases catalyse a two-step reac-
tion whereby an ATP and amino acid molecule (AA) enter the ac-
tive site, forming an aminoacyl-adenylate intermediate (1),followed by the esteriﬁcation of the amino acid to the 30 end of
the tRNA, forming the ﬁnal ‘charged’ aminoacyl-tRNA (2).
AAþ ATPþ AARS AARS  AA-AMPþ PPi ð1Þ
AARS  AA-AMPþ tRNA AARSþ AA-tRNAþ AMP ð2Þ
This presents several sites on aaRS enzymes that may be consid-
ered for drugging purposes; a binding site for ATP, an adjacent ami-
no acid binding site, and a fold for tRNA recognition and binding
(Fig. 1). Most aaRS inhibitors bind to the ATP and amino acid bind-
ing sites, in many cases as analogues of ATP, amino acids, or ami-
noacyl-adenylate intermediates (Vondenhoff and Van Aerschot,
2011). Below we review prospects for antiparasitic drug develop-
ment from such inhibitors for each of the tRNA synthetases.
Discrimination between different amino acids with similar chemi-
cal structures is a biochemical challenge and some aminoacyl-tRNA
synthetases are prone to errors in charging. Errors can be reduced by
recognition and elimination of misactivated noncognate amino acids,
or through editing of misacylated tRNAs. Proof-reading is achieved
both through editing domains on the aaRS enzymes themselves, as
well as by stand-alone editing enzymes (Ahel et al., 2003; Sokabe
et al., 2005). These domains and enzymes have the potential to act
as targets for drugs, and several aaRS inhibitors are thought to act
via inhibition of the editing process (Rock et al., 2007; Tan et al., 2013).
In addition to their canonical roles in tRNA aminoacylation,
these ancient enzymes have also evolved extra functions, in some
cases through the acquisition of novel protein domains (Lee et al.,
2004; Smirnova et al., 2012; Guo and Schimmel, 2013). In eukary-
otes in particular, tRNA synthetases also play roles in non-transla-
tion processes including the regulation of transcription, RNA
splicing, apoptosis, angiogenesis, immune responses and signalling
events. These moonlighting functions may be crucial in some
organisms, and some inhibitors that focus speciﬁcally on these
non protein-translation roles of aaRSs have been explored. Non-
canonical roles have been suggested for several parasite tRNA syn-
Table 1
Representative inhibitors of aminoacyl tRNA synthetases in parasites and other infectious agents. The names of the structures shown are indicated in bold text. Structures are
derived from PubChem, Chemspider or redrawn from original papers.
Target Compound name Comments  References Structure Parasite
Mechanism
of action 
AlaRS A3; A5
In silico docking against the 
P. falciparum AlaRS identified 
several compounds that inhibited 
parasite growth in culture 
(Khan et al., 
2011)
Plasmodium
falciparum Active site* 
AsnRS
Variolin B,
Rishirilide B, 
Cycloadenosine,
Phenanthridinol,
Triazinylamine,
Phenanthrylethanon
e,
Dimethylmalonamid
e
Compounds identified from in silico
screen against the Brugia malayi 
AsnRS protein structure identified 
some that inhibited BmAsnRS in a 
pretransfer assay. Some 
compounds with selectivity 
compared to human AsnRS. 
(Sukuru et al., 
2006) Brugia malayi Active site* 
AsnRS
Natural product 
extracts (199 in 
total) (L-aspartate-
β-hydroxamate)
Natural product extracts inhibit the 
pre-transfer editing of the Brugia
malayi AsnRS. Established a pre-
transfer editing assay using 
malachite green. 
(Danel et al., 
2011) Brugia malayi 
Pre-transfer
editing site* 
AsnRS
Tirandamycins
(TAM) A; TAM B;
TAM E; TAM F; 
TAM G 
Natural compounds isolated from 
Streptomyces sp. 17944 extracts. 
TAM B was the most potent with an 
IC50 of 30 µM against BmAsnRS
and killed adult worms in culture.
(Yu et al., 
2011) Brugia malayi 
Pre-transfer
editing site* N
OO
O
OO
O
OO
H
H
H
N N
O
O
O O
H
H
H3
+
-
N
N
N
N
N
N
N
O
H
H
H2
2
N
O
O
O
O -+
AsnRS
WS9326A (1); 
WS9326C (2); 
WS9326D (3); 
WS9326E (4) 
Natural compounds isolated from 
Streptomyces sp. 9078. WS9326D 
inhibits Brugia AsnRS activity, kills 
adult B. malayi parasites in culture, 
and has low cytotoxic to human 
hepatic cells. 
(Yu et al., 
2012) Brugia malayi 
Pre-transfer
editing site* 
IleRS
Mupirocin
(pseudomonic acid) 
Kills ex vivo cultured Plasmodium
falciparum; delayed death 
phenotype. Mupirocin is clinically 
used for topical treatment of 
bacterial skin infections 
(Istvan et al., 
2011)
Plasmodium
falciparum Active site 
IleRS 4-Thiaisoleucine 
Isoleucine analogue, competitive 
inhibitor of cytosolic IleRS. Inhibits 
growth of in vitro Plasmodium
parasites at micromolar 
concentrations.
(Istvan et al., 
2011; Liu et 
al., 2006) 
Plasmodium
falciparum Active site* 
IleRS
Ile-AMP analogues 
(21 in total)  – 
NSC70422 shown 
Inhibits growth of T. brucei
bloodstream forms. Selective 
compared to mammalian cells. 
Compound NSC70422 is 
competitive inhibitor of T. brucei 
IleRS and cures mice of infection. 
(Cestari and 
Stuart, 2013) 
Trypanosoma
brucei Active site* 
N
N
NNN
O
O
O
O
OOO
O
O
O
H
H
H H
H
HH
H
H3C
N
O
O
H
H
2
S
N
NN
N
N
O
O
O
O
H
H
H
H2
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LeuRS 
Benzoxaborole 
derivatives ( 26
shown) 
Compounds inhibit aminoacylation 
by TbLeuRS and growth of T. 
brucei bloodstream forms in culture. 
Low mammalian cell cytotoxicity. 
(Ding et al., 
2011) 
Trypanosoma 
brucei 
Post-
transfer 
editing site* 
LeuRS 
2-Pyrrolinone 
derivatives ( 8
shown) 
Virtual screening approach with in 
silico docking and pharmacophore 
to guide compound synthesis. 
Compounds inhibited in TbLeuRS 
activity in mid-micromolar range. 
(Zhao et al., 
2012) 
Trypanosoma 
brucei Active site* 
LeuRS 
N-(4-
sulfamoylphenyl) 
thioureas 
derivatives ( 59
shown) 
Inhibited TbLeuRS at low 
micromolar concentrations with 
moderate selectivity compared toor 
human cytoplasmic LeuRS. 
Compounds showed poor 
permeability and did not inhibit 
T. brucei growth in culture. 
(Zhang et al., 
2003) 
Trypanosoma 
brucei Active site* 
LysRS Cladosporin 
Inhibit blood and liver proliferation 
of P. falciparum at the nanomolar 
range through interaction with the 
cytoplasmic LysRS. Selectivity for 
PfLysRS compared to human 
LysRS. 
(Hoepfner et 
al., 2012) 
Plasmodium 
falciparum Active site 
LysRS2 
(Apicopl
ast) 
Lysyl-adenylate 
analogues (50 in 
total) ( M-26  shown) 
Selective inhibitors of apicoplast 
LysRS. No inhibition of cytosolic 
LysRS or human lysRS homologue. 
Kills in vitro cultured P. falciparum
with delayed death phenotype. 
(Hoen et al., 
2013) 
Plasmodium 
falciparum Active site* 
O
O
O
O
O
H
B
N
N
N NS
S O
OOO
O
H
H HH
2
Cl
Br
O O
O
OH
OH
H
H 3C
N
N
N
N
N
S O
O
O
O
H H
H
2
NH2 NH2
Br
MetRS 
Aminoquinolone 
derivatives (21 in 
total series); 
benzimidazoles; 2-
amino-8-hydroxy-
quinoline ( 1312 
shown) 
Compounds selectively inhibit 
TbMetRS and the growth of 
bloodstream form T. brucei in 
culture. Low toxicity for mammalian 
cells. Compounds suppress 
parasitaemia in a mouse model but 
not curative. 
(Shibata et al., 
2011) 
Trypanosoma 
brucei Active site 
MetRS 
Urea-based 
inhibitors series ( 26
shown) 
Selective inhibitors of TbMetRS 
compared to human MetRS and 
inhibited T. brucei growth in culture. 
Compounds were cell-permeable, 
had good pharmacokinetics and 
low cytotoxicity against mammalian 
cells. 
(Shibata et al., 
2012) 
Trypanosoma 
brucei Active site 
MetRS REP8839 
Potent bacteriostatic activity against 
S. aureus and various other gram-
positive bacteria. Currently being 
evaluated for topical treatment for 
S. aureus infections. 
(Critchley et 
al., 2005) 
Staphylococcus 
aureus, 
Streptococcus 
pyogenes Active site 
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ThrRS Borrelidin 
Specific inhibitor of fungal ThrRS. 
Kills ex vivo cultured Plasmodium
falciparum, cures mice of P. yoelii. 
Rapid death phenotype in blood 
stage parasites. 
(Otoguro et al., 
2003) 
Plasmodium 
falciparum,  
Plasmodium 
yoelii Active site* 
ThrRS 
Borrelidin 
analogues 
Kills Plasmodium falciparum blood 
stages (K1 and FCR3 strains) in 
culture. Reduced cytotoxicity 
against human cells compared to 
borrelidin. 
(Sugawara et 
al., 2013) See above. 
Plasmodium 
falciparum Active site* 
ThrRS 
T1; T2; T3; T4; T5; 
T6; T7; T8; T9; T10; 
T11 
Compounds tested against cultured 
P. falciparum. All displayed > 
100µM IC50. 
(Khan et al., 
2011) 
Plasmodium 
falciparum Active site* 
MetRS REP3123 
A novel diaryldiamine that displays 
antimicrobial activity to a spectrum 
of clinically important gram-positive. 
Inhibits toxin production and 
sporulation of C. difficile in vitro.  
(Critchley et 
al., 2009) 
Clostridium 
difficile Active site 
ProRS Halofuginone (HF) 
Febrifugine derivative: nanomolar 
inhibitor of sporozoite propagation 
in ex vivo hepatocytes and cultured 
P. falciparum in erythrocytes. HF 
inhibition is ATP-dependant. Phase 
II clinical trials for cancer/fibrosis - 
Antimalarial in vivo mouse studies. 
(Keller et al., 
2012; Zhou et 
al., 2013) 
Plasmodium 
falciparum 
Active site: 
(1) proline 
binding 
pocket; (2) 
3' end tRNA 
binding site 
aPredicted site of action. (See above-mentioned references for further information.)
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drug targets below.4. Existing aaRS inhibitors in parasites
4.1. Alanyl-tRNA synthetase
Alanyl-tRNA synthetase (AlaRS) has been a focus of extensive
research due to the presence of an unusual secondary catalytic
site with editing activity (Guo et al., 2009; Sokabe et al.,
2009). Glycine and serine are common misacylations of tRNAAla,
and AlaRS enzymes can edit these products of misacylation to
ensure they do not accumulate to toxic levels. Mice with defects
in tRNAAla editing have a neurodegeneration phenotype, reinforc-
ing the importance of editing activity (Lee et al., 2006). An AlaX
domain found on additional proteins is also involved in the elim-
ination of mischarged tRNAAla and an AlaX domain has been re-
ported in Plasmodium, fused to another tRNA synthetase; PfTrpRS
(Khan et al., 2013b). AlaRS has also been characterised in Plas-
modium parasites—only one version of this enzyme is encoded
by the Plasmodium genome, despite apparent requirements for
cytosolic organellar translation. As with the PfGlyRS and PfThrRS,
this enzyme is post-translationally targeted to both the Plasmo-
dium falciparun cytosol and the apicoplast, possibly by produc-
tion of alternatively initiated proteins (Khan et al., 2011;
Jackson et al., 2012). Khan et al. (2011) screened several putative
inhibitors of the PfAlaRS based on in silico docking against struc-
tural homology models. One of these, 4-{2-nitro-1-propenyl}-1,2-
benzenediol (Table 1), inhibited parasite growth at low micro-
molar inhibition, and produced only limited mammalian cytotox-
icity at similar concentrations (Khan et al., 2011). Although it isnot yet known if these compounds inhibit the parasite PfAlaRS,
the dependence of cytosolic and apicoplast translation on this
dual targeted enzyme makes it a conceptually attractive target.4.2. Asparaginyl-tRNA synthetase
The cytoplasmic asparaginyl-tRNA synthetase (AsnRS) has been
a long-standing drug target in Brugia malayi, a nematode that is
one of the causative agents of lymphatic ﬁlariasis. This enzyme is
very highly expressed compared to other Brugia aaRSs, and, like
other aaRSs mentioned above, appears to have developed non-pro-
tein-translation functions in addition to its canonical role. In Bru-
gia, the AsnRS is an immunodominant antigen in human
infections (Kron et al., 1995) additionally this enzyme catalyses
the production of diadenosine triphosphate (Kron et al., 2003)
and exhibits immunomodulatory functions associated with inﬂam-
mation during host infection (Ramirez et al., 2006; Kron et al.,
2012, 2013). Because of these apparently key roles, several drug
discovery (and diagnostic) projects have focused on this B. malayi
enzyme.
Two distinct strategies have been employed to ﬁnd inhibitors of
the B. malayi enzyme; in silico docking and high throughput screen-
ing. In the ﬁrst approach, compounds from publicly available col-
lections were docked against the B. malayi AsnRS (BmAsnRS).
From this docking, 45 compounds were tested for their inhibition
of the BmAsnRS, as assayed by a modiﬁed malachite green assay,
which provides a readout for the ﬁrst step in aminoacylation reac-
tion. Of the compounds screened, a handful inhibited AsnRS
aminoacylation at mid-micromolar IC50s (Table 1) (Sukuru et al.,
2006). Subsequent publication of a more detailed structure for
the Brugia AsnRS in complex with a substrate analogue that acts
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tional information to reﬁne future docking experiments or to ratio-
nally improve existing inhibitors.
A second approach makes use of an assay that focuses on
AsnRS’s capacity to recognise and edit misacylation prior to
transfer. This pre-transfer editing assay initially identiﬁed com-
pounds that promoted the editing activity of BmAsnRS, as well
as allowing screening of inhibitors that blocked the BmAsnRS
(Table 1) (Danel et al., 2011). The assay was then used to exper-
imentally screen for inhibitors of BmAsnRS among tens of thou-
sands of extracts from diverse microbial strains. Further
puriﬁcation and fractionation of these extracts has led to the dis-
covery of two different compound classes—the Tirandamycins
(Yu et al., 2011) and the WS9326A derivatives (Yu et al., 2012)
(see Table 1)—that each inhibit BmAsnRS aminoacylation and kill
adult B. malayi. Both classes appear to show some selectivity for
Brugia compared to human AsnRS. Further optimisation and val-
idation of these inhibitors is reportedly underway (Yu et al.,
2011; Rateb et al., 2013).
4.3. Isoleucyl-tRNA synthetase
The protist parasite, Trypanosoma brucei is the causative agent
of human African trypanosomiasis. There is an urgent need for
new, more effective, non-toxic, and cheap antitrypanosomal drugs
(Fevre et al., 2008). Recent research validates the Trypanosoma bru-
cei isoleucyl-tRNA synthetase (IleRS) as a potential drug target,
with ex vivo and in vivo RNAi knockdowns showing IleRS to be
essential for Trypanosoma brucei growth (Cestari and Stuart,
2013). Cestari and Stuart screened 20 compounds from the Na-
tional Cancer Institute database that were structurally similar to
Ile-AMP (the reaction intermediate) for killing of T. brucei blood-
stream forms. Several active compounds from this screen, includ-
ing NSC70442 speciﬁcally inhibited activity of recombinant T.
brucei isoleucyl-tRNA sythetase (IleRS) and have good selectivity
against mammalian cell lines (Table 1). Furthermore, a transgenic
T. brucei line that overexpressed IleRS showed reduced sensitivity
to NSC70442 and other Ile-AMP analogues, supporting IleRS as
the target of these inhibitors. NSC70442 cured in T. brucei-infected
mice at low mammalian toxicity (Cestari and Stuart, 2013). There
is also evidence that compounds from this chemical class are able
to cross the blood brain barrier (Cestari and Stuart, 2013), a very
important characteristic for antitrypanosomal drugs that can treat
stage 2 trypanosomiasis (Rottenberg et al., 2005)
The most widely-used drug that inhibits aminoacyl-tRNA syn-
thetases targets IleRS. Mupirocin (also known as pseudomonic
acid, and marketed as Bactroban), is used for the topical treat-
ment of Staphylococcus aureus. Crystal structures of mupirocin-
bound IleRS indicate that mupirocin inhibits bacterial IleRS by
blocking the binding of the Ile-AMP intermediate (Nakama
et al., 2001). Mupirocin has now been shown to inhibit blood-
stage P. falciparum growth in the nanomolar range (Table 1) (Ist-
van et al., 2011). Mupirocin resistant Plasmodium parasites have
mutations in the apicoplast-located IleRS, indicating that the
bacterial type apicoplast IleRS is the target of mupirocin (Istvan
et al., 2011). This is supported by speciﬁc defects in apicoplast
morphology and segregation upon mupirocin, and in the ‘‘de-
layed-death’’ type mupirocin killing of ex vivo cultured parasites
(Jackson et al., 2012), which is characteristic of inhibitors block-
ing apicoplast maintenance. Mupirocin failed to protect mice
from a Plasmodium berghei infection, a likely result of the com-
pound’s well known in vivo instability and its high binding to
serum (Casewell and Hill, 1987). Mupirocin itself is therefore
very unlikely to serve as a good lead for antiparasitic drug devel-
opment, but does validate the apicoplast IleRS as a target for
speciﬁc antimalarial drug research. Istvan and colleagues (Istvanet al., 2011) also showed that the Plasmodium cytosolic IleRS was
inhibited by the isoleucine analogue thiaisoleucine (Table 1),
which rapidly killed ex vivo cultured parasites. Thiaisoleucine
also inhibits mammalian IleRS but its inhibition of Plasmodium
growth supports the Plasmodium cytosolic IleRS enzyme as a po-
tential drug target. Another inhibitor of eukaryotic IleRSs, the
cyclic beta amino acid, icofungipen, shows good activity against
pathogenic fungi, and has been through phase II human trials
(Hasenoehrl et al., 2006). We are unaware of any tests on the
activity of icofungipen in any parasite.
4.4. Leucyl-tRNA synthetase
LeuRS is a proofreading aaRS that is inhibited by 5-ﬂuoro-1,3-
dihydro-1-hydroxy-2,1-benzoxaborole (AN2690) by trapping
tRNALeu in the editing site (Rock et al., 2007). AN2690 has potent
antifungal activity, and was reported to be undergoing clinical
trials (Seiradake et al., 2009). Inspired by this success story,
inhibitors based on the benzoxaborole core—that contains a
boronic acid and forms an adduct with the tRNA—were explored
as LeuRS inhibitors for T. brucei. For this purpose, a homology
model of the T. brucei CP1 (editing) domain based on the solved
Candida albicans LeuRS was used to design a series of benzoxab-
orole compounds (Ding et al., 2011). Structure–activity relation-
ship was studied, and the best of the compounds (Table 1)
inhibited TbLeuRS aminoacylation and T. brucei ex vivo growth
at low micromolar IC50s, with low mammalian cell toxicity (Ding
et al., 2011). A subsequent TbLeuRS study (Zhao et al., 2012),
used a homology model based on the solved Pyrococcus horiko-
shii LeuRS structure (Fukunaga and Yokoyama, 2005) and instead
targeted the enzyme’s synthetic site. This study performed in sil-
ico screening with the SPECS chemical library, and tested a range
of compounds with a 2-pyrrolinone scaffold against an in vitro
TbLeuRS aminoacylation assay. Though a diverse group of ana-
logues showed some structure–activity relationship, inhibition
occurred only at rather high concentrations, with the most po-
tent compounds showing IC50s between 30 and 100 lM (Ta-
ble 1) (Zhao et al., 2012).
More recently, a new class of T. brucei LeuRS inhibitors, N-(4-
sulfamoylphenyl)thioureas, which targets the synthetic catalytic
site, has been discovered through the screening and modiﬁcation
of a small, targeted library of putative aaRS inhibitors (Zhang
et al., 2013). This class of inhibitors are designed to inhibit by
mimicking the intermediate product, aminoacyl-AMP. To further
improve upon the activities of the compounds, TbLeuRS was
used to dock inhibitors and guide synthesis of derivatives. The
best compound, 59, showed an IC50 of 1.1 lM and is predicted
to form four hydrogen bonds and favourable hydrophobic inter-
actions with the synthetic enzyme pocket. These compounds
exhibited moderate selectivity (4.5–7.3 fold) compared to human
cytoplasmic LeuRS, but none of the compounds optimised for
inhibition of the synthetic site inhibited growth of T. brucei in
culture at 100 lM (Table 1). Experiments using caco-2 cell per-
meability assays indicated that these compounds have poor per-
meability and may explain the poor inhibition seen in the
ex vivo bioassays. This new inhibitor class shows early promise
as TbLeuRS inhibitors but will require more work to address per-
meability issues and demonstrate the ability to kill parasites and
cure mice infections.
4.5. Lysyl-tRNA synthetase
In a recent comprehensive study, the fungal secondary
metabolite cladosporin (Table 1) was shown to inhibit blood
and liver proliferation of P. falciparum at the nanomolar range
(Hoepfner et al., 2012). Studies in fungi showed that heterozy-
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fungi with separate point mutations in LysRS were more resis-
tant to cladosporin. Plasmodium parasites overexpressing the
cytosolic PfLysRS are similarly more resistant to cladosporin. In
silico docking suggests that cladosporin interacts with the ATP-
binding pocket of the LysRS and increasing concentration of
ATP in vivo signiﬁcantly reduced inhibition, consistent with this
in silico prediction. Cladosporin only demonstrated weak inhibi-
tion of recombinant human LysRS at high micromolar concentra-
tions, which was postulated to be due to steric hindrance within
the ATP-binding pocket (Hoepfner et al., 2012). The crystal struc-
ture of the cytoplasmic PfLysRS was subsequently solved, and
conﬁrms a structural difference in this region is likely to be
the basis for this selectivity (Khan et al., 2013a). The structure
also describes additional differences that may allow for the de-
sign of selective inhibitors that act against the Plasmodium but
not human LysRS (Khan et al., 2013a).
Whilst cladosporin inhibits the Plasmodium cytosolic LysRS,
Hoen and colleagues (Hoen et al., 2013) have pursued the api-
coplast PfLysRS isoform as a potential drug target. They con-
structed a virtual lysyl-adenylate mimic compound library and
screened this through in silico docking against a homology model
of P. falciparum apicoplast LysRS. Two of the tested compounds
(M-26 and M-37), had potent delayed death inhibition (consis-
tent with apicoplast-speciﬁc activity) and inhibited aminoacyla-
tion by recombinant apicoplast PfLysRS (Table 1) (Hoen et al.,
2013). The availability of speciﬁc inhibitors for both the cyto-
plasmic LysRS and the apicoplast LysRS provides ideal tools for
studying the relative importance of organellar and cytosolic
tRNA synthetases as well as providing promising drug leads.
Cladosporin itself possesses poor oral bioavailability and seems
therefore to be a poor drug candidate itself (Hoepfner et al.,
2012), but may serve as a chemical starting point for other
PfLysRS inhibitors.
4.6. Methionyl-tRNA synthetase
One series of compounds that has been investigated as antitry-
panosomal agents was inspired by the success of the bacterial Met-
RS diaryl diamines inhibitors (Table 1) (Critchley et al., 2009).
These bacterial inhibitors are highly selective for bacterial versus
mammalian enzymes. Some of these compounds do inhibit recom-
binant human mitochondrial MetRS, however no cytotoxicity of
mammalian cell cultures is apparent (Green et al., 2009). Homol-
ogy models based on several MetRS structures were used to guide
synthesis of related T. brucei MetRS inhibitors (Table 1), and these
were tested for binding to TbMetRS (Shibata et al., 2011). Inhibition
of aminoacylation activity was assayed at 50 nM and the most
interesting of compounds showed >95% inhibition of activity at
this concentration. Compounds were also screened using ex vivo
cultures of T. brucei (and Trypanosoma cruzi) and the most effective,
compound 1, had an EC50 of 4 nM and low toxicity for mammalian
cells. Compound 1 was delivered at 25 mg/kg/day for 3 days using
subcutaneous osmotic minipump to circumvent issues with bio-
availability, and showed initial suppression of parasitaemia but
mice later succumbed to disease (Shibata et al., 2011). Partial
knockdown of the T. brucei MetRS through RNAi produced a severe
growth defect, conﬁrming the importance of this enzyme (Shibata
et al., 2011).
Two subsequent studies characterised structures of the Leish-
mania MetRS (Larson et al., 2011b) and the TbMetRS (Koh et al.,
2012) bound to substrates, Met, MetAMP and, in the case of the
TbMetRS, inhibitors. This study revealed extensive conforma-
tional rearrangement by the TbMetRS structure upon inhibitor
binding, suggesting conformation selection as the basis for bind-
ing (Koh et al., 2012). Inspection of the structures showed exten-sive rearrangement of the conformations occurred with
introduction of inhibitors—with the compound occupying a
pocket that was not present with substrates Met or MetAMP—
called the auxillary pocket. The crystal structure of ligand-free
TbMetRS1 is very similar to the inhibitor-bound conformation
of TbMetRS and supports the idea that conformational selection
is the likely model for binding of inhibitors to TbMetRS (Koh
et al., 2012). The LmMetRS structure additionally revealed sev-
eral differences from its human homologs near the active site
that might be exploited with inhibitors that could speciﬁcally
target the parasite enzyme (Larson et al., 2011b).
To improve upon the earlier MetRS inhibitors that exhibited
poor PK proﬁles and poor bioavailability (Jarvest et al., 2002,
2003), the authors made a follow up compound series (Table 1)
(Shibata et al., 2012). Guided by structures of inhibitor-bound
MetRS, it was rationalised that a urea-based scaffold would in-
crease bioavailability. The enzymes were screened using a ther-
mal shift binding assay then used in in vitro aminoacylation
assays to test for inhibition of TbMetRS and HsMitoMetRS. Com-
pounds had similar IC50 and selectivity to the original series and
improved pharmacokinetic characteristics, but unfortunately the
oral bioavailability remained poor. Nonetheless these authors
have demonstrated the importance of this enzyme for parasite
growth, as well as the capacity to design speciﬁc inhibitors
against trypanosomatid MetRS, and this remains a highly prom-
ising target.
4.7. Prolyl-tRNA synthetase
One long-used traditional antiparasitic agent, febrifugine, has
recently been revealed to inhibit prolyl tRNA synthetase. This qui-
nazolinone alkaloid is a constituent of the Chinese herbal medicine,
Chángsa¯n (Dichroa febrifuga). Despite excellent antiparasitic activ-
ity, its strong liver toxicity and gastrointestinal side effects have
limited the use of febrifugine as a widespread therapeutic. Febrifu-
gine analogues have been synthesised with a reduced capacity to
form toxic intermediates and have demonstrated potent inhibition
of P. falciparum isolates in ex vivo culture, P. berghei in vivo infection
and impressive cure rates in an in vivo Aotus monkey model (Zhu
et al., 2010, 2012). One of these analogues, the synthetic haloge-
nated derivative halofuginone (Table 1), potently inhibits cultured
erythrocytic and liver stage Plasmodium falciparum (Kobayashi
et al., 1999; Derbyshire et al., 2012; Keller et al., 2012). Halofugi-
none has been a US FDA (Food and Drug Administration) approved
drug for apicomplexan parasite (coccidia) infections of chickens
and turkeys since the 1980s and is currently involved in both Stage
I and Stage II clinical trials for use against proliferative diseases
that include carcinoma, advanced solid tumours and AIDs related
malignancies (Folz et al., 1988; Elkin et al., 1999; de Jonge et al.,
2006; Koon et al., 2011).
Recent papers have demonstrated that halofuginone and other
febrifugines act through inhibition of ProRS. In an elegant study,
Keller et al. (2012) demonstrated ﬁrst that halofuginone (which
was known to activate the amino acid starvation response) inhib-
ited an in vitro translation assay, and translation was restored only
by addition of excess proline. Halofuginone also bound to and
inhibited recombinant human ProRS. Addition of excess proline
also reduced the sensitivity of P. falciparum parasites to halofugi-
none (Keller et al., 2012). A subsequent study showed that halofu-
ginone speciﬁcally blocks the formation of the Pro-AMP adenylate
complex (Zhou et al., 2013). Interestingly, the inhibition is reliant
on the presence of ATP to allow high afﬁnity binding of halofugi-
none to ProRS. ATP directly assists the orientation of halofuginone
to enable one end to occupy the proline binding site and conse-
quently, to competitively block activation of this amino acid, whilst
the other end simultaneously mimics the 30 end of the tRNA mol-
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also been modelled with the P. falciparum ProRS, which is predicted
to recapitulate these dual site enzyme inhibition interactions
(Zhou et al., 2013). The apparent efﬁcacy of febrifugines as antima-
larial agents, despite their obvious inhibition of human ProRS and
proliferating human cells serves as a reminder that drug selectivity
for an acute parasitic infection need not necessarily rely on molec-
ular speciﬁcity.
4.8. Threonyl-tRNA synthetase
Borrelidin, ﬁrst isolated from Streptomyces spp., acts as a non-
competitive, selective inhibitor that binds to a unique hydropho-
bic cluster near the active site of some bacterial and eukaryotic
ThrRS enzymes (Nass and Hasenbank, 1970; Ruan et al., 2005;
Gao et al., 2012). Borrelidin is an inhibitor of yeast cyclin-depen-
dent kinase (Tsuchiya et al., 2001) and an activator of pro-apop-
totic mediators in endothelial cells (Kawamura et al., 2003).
Several investigations on the effect of borrelidin on Plasmodium
shine light on its presumed target PfThrRS (Table 1). Borrelidin
potently inhibits parasite proliferation in culture, with an imme-
diate effect on the ﬁrst asexual erythrocytic life-cycle after treat-
ment, typical of cytosolic inhibition. This inhibition is unlike the
delayed-death seen for apicoplast inhibitors (Ishiyama et al.,
2011; Jackson et al., 2012; Azcarate et al., 2013) and borrelidin
does not appear to inhibit organellar division (Jackson et al.,
2012). Plasmodium possesses only one PfThrRS, a dual-targeted
enzyme, which is trafﬁcked to the apicoplast and cytosol (Khan
et al., 2011; Jackson et al., 2012). The immediate inhibition seen
with Borrelidin is consistent with the requirement of this
PfThrRS for cytosolic translation. Although the exact molecular
mechanism responsible for the antimalarial effect of borrelidin
remains unclear, raised concentrations of L-Threonine in culture
reduce parasite sensitivity, thus implicating threonine utilisation
and PfThrRS as likely targets of borrelidin (Ishiyama et al., 2011).
In addition to its ex vivo use, borrelidin has been shown to cure
mice of rodent malaria infections (Otoguro et al., 2003; Azcarate
et al., 2013), with one report of borrelidin-cured mice then acquir-
ing protection from subsequent challenge by Plasmodium yoelii
(Azcarate et al., 2013). Although, borrelidin displays some mam-
malian cytotoxicity, there are efforts to synthesise borrelidin ana-
logues with decreased toxicity (Wilkinson et al., 2006; Sugawara
et al., 2013). More recently, Sugawara et al. (2013) generated a bor-
relidin-like series (Table 1) that reduced the cytotoxicity whilst
simultaneously increasing the antimalarial activity, an important
step to further progress the development of borrelidin as a future
antimalarial drug.
Khan et al. (2011) have also investigated novel inhibitors of the
PfThrRS predicted by in silico docking of small molecule compound
libraries against homology models of the PfThrRS. The best of these
compounds showed only moderate inhibition (IC50 from 75 to
150 lM) of ex vivo P. falciparum growth (Table 1) (Khan et al.,
2011).
4.9. Tryptophanyl-tRNA synthetase
Considerable divergence in sequence and structure of TrpRSs
has previously been described across the three domains of life.
This has attracted some interest for TrpRS as a drug target,
including in parasites. In trypanosomatid parasites this diver-
gence is compounded by the requirement for an additional
TrpRS that charges a non-canonical UGA-recognising tRNATrp re-
quired in the parasite’s mitochondria. This tRNA is encoded by
the same gene as that used for cytosolic translation, but the ver-
sion used in the mitochondria is ﬁrst chemically altered through
thiol modiﬁcation and C to U nucleotide editing at the ﬁrst posi-tion of the anticodon (Alfonzo et al., 1999). T. brucei encodes two
TrpRS enzymes – one that recognises only the canonical tRNA in
the cytosol, plus a second that recognises the altered tRNA in the
mitochondrion (Charriere et al., 2006). This later TbTrpRS is line-
age speciﬁc, and presents opportunities for selective inhibition. A
similar scenario may exist in the apicoplast of apicomplexan par-
asites, where the UGA in the apicoplast genome also appears to
be partially decoded as tryptophan rather than a stop codon
(Wilson, 2002).
Structural analysis of TrpRS enzymes from various parasites
also appears to offer opportunities for selective drug development.
Analysis of the crystal structure of TrpRS from Giardia lamblia re-
vealed a 16-residue a-helix instead of the hydrophobic ß-hairpin
that stabilises the bond between tryptophan and the enzyme (Ara-
kaki et al., 2010). The Toxoplasma and Trichomonas sequences also
diverge from the human sequence in this area (Arakaki et al.,
2010). These are important sub-domains of the human enzyme,
so these marked differences may provide a means of selectively
inhibiting the parasite homologues. Additional structures for the
T. brucei cytosolic TrpRS (Merritt et al., 2011), the Cryptosporidium
parvum TrpRS (Merritt et al., 2011), and the P. falciparum TrpRS
(Khan et al., 2013b; Koh et al., 2013) also reveal some additional
parasite speciﬁc sub-domains or structural differences that might
be exploited for drug design purposes. A structure has also been
solved for a divergent member of three identiﬁed Entamoeba his-
tolytica TrpRS homologues, but this enzyme lacks Trp binding
and is unlikely to charge tRNATrp (Merritt et al., 2011).
Although no inhibitors have thus far been reported for parasite
TrpRSs, several chemical starting points exist for exploration; bac-
terial TrpRS are inhibited by natural products and tryptophan ana-
logues such as indolmycin (Rao, 1960; Kanamaru et al., 2001) and
chuangxinmycin (Brown et al., 2002).4.10. Tyrosyl-tRNA synthetase
To our knowledge tyrosyl-tRNA synthetases (TyrRS) have yet to
be experimentally investigated as targets for drug development in
parasites. However, previous studies have identiﬁed inhibitors ac-
tive against bacterial TyrRS including the naturally derived SB-
219383 (Berge et al., 2000; Stefanska et al., 2000; Greenwood and
Gentry, 2002) and several synthetic compounds (Jarvest et al.,
1999; Xiao et al., 2011a,b;Wang et al., 2013). The few parasite-spe-
ciﬁc studies on TyrRS focused on the structural aspects of the en-
zyme. Bhatt and colleagues (Bhatt et al., 2011), localised the
cytosolic PfTyrRS to the parasite cytoplasmand noted the additional
presence of PfTyrRSwithin infected erythrocytes. These authors also
detected extracellular activity of PfTyrRS through mimicry of host
cytokines to induce host immune system pro-inﬂammatory re-
sponses (Bhatt et al., 2011). In addition to this intriguing discovery,
Bhatt et al. solved the crystal structure of PfTyrRS in complex with
tyrosyl-adenylate (Bhatt et al., 2011). Structural comparisons be-
tween the Plasmodium and human TyrRS revealedmany differences
such as the organisation of loop structures and included sequence
level differences at 11 residues that contribute to binding of sub-
strate (Bhatt et al., 2011). The crystal structure of the unusual dou-
ble-length TyrRS orthologue from Leishmania major suggest a
pseudo-dimer that is formed by asymmetric domains (Larson
et al., 2011a) that also differs from the host TyrRS. Taken together
these differences could potentially be exploited for design of struc-
ture-based inhibitors of parasite TyrRSs.5. Concluding remarks
As evident in the list of targets above, much of the research
on parasite aminoacyl-tRNA synthetases has taken place over
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classical biochemistry, and a small initial number of chemical
starting points, the research community is now using a myraid
of technologies to investigate aaRSs and has built up an array
of inhibitors that represents diverse chemical space. An encour-
aging development is the recent discovery of new chemicals that
inhibit aaRS in eukaryotic parasites including Brugia, Trypano-
soma and Plasmodium parasites (Table 1). Detailed structural re-
search has shed important light on the structural basis for
aminoacylation, and provides us with insights into the number
of ways in which these enzymes can be chemically inhibited.
In silico docking, rational design of compounds to ﬁt into active
sites, as well as high throughput screening have all resulted in
the identiﬁcation of compounds that potently inhibit aaRSs. Sev-
eral combinatorial and medicinal chemistry programs have mod-
iﬁed these starting compounds to develop compounds with
acceptable pharmaceutical properties, and there are promising
animal-model data for aaRS inhibitors for several parasites. Fu-
ture investigations will need to consider whether these can gen-
uinely be developed as drug like compounds, and if so, whether
this can be achieved cheaply – a prime consideration for ne-
glected parasitic diseases.
Advances across a number of systems biology platforms are
accelerating the ability to make connections between inhibitors
and molecular targets in parasites, and to subsequently validate
these targets. Identifying resistance mutations that shed light on
modes of action has been a long standing means of interrogating
aaRS inhibitors. Alongside the current availability and reduced cost
of next-generation sequencing technologies now means that target
identiﬁcation has become feasible and affordable for the larger
eukaryotic parasite genomes. A number of resistance mapping
studies for aaRS inhibitors in Plasmodium set a standard for future
investigations in this genre (Istvan et al., 2011; Hoepfner et al.,
2012).
Two concerns, selectivity and resistance, will remain major
challenges for the development of antiparasitic aaRS inhibitors.
Despite these parasites being only very distantly related to each
other, and cause very different diseases, they share the chemo-
therapeutic challenge of ﬁnding drugs that select between one
eukaryote and another (humans). Selectivity is a major issue be-
cause the human genome encodes for 36 aminoacyl-tRNA syn-
thetase, (16 cytoplasmic, 17 mitochondrial, 3 dual-targeted)
(see review by Antonellis and Green (2008)) that have eukaryotic
and bacterial origins (mitochondria). Avoiding inhibition of the
most conserved homologs is a challenge in aaRS inhibition to
avoid potential cytotoxicity. Strategies to circumvent host toxic-
ity include exploitation of organellar, bacterial-type aaRSs where
the human homologue is divergent (such as the Leishmania
AsnRS with a bacterial origin (Gowri et al., 2012)) or exploitation
of parasite-speciﬁc modiﬁcations (Bour et al., 2009). It should
also be kept in mind that for the protist parasites at least, they
are separated by a billion years of evolution from their mamma-
lian hosts, so molecular divergence abounds. In all of these cases,
structural information is often key to identifying exploitable dif-
ferences between host and parasite (Bunjun et al., 2000; Larson
et al., 2011a). It is noteworthy that it is sometimes possible to
design aaRS inhibitors with good selectivity even where few dif-
ferences exist in active site residues between parasite and host
(Shibata et al., 2011).
Resistance to antiparasitic drugs is a major concern. Eventual
resistance to aaRS inhibitors is inevitable, and can only be hoped
to be delayed, but this unfortunate outcome is often overlooked
in the preclinical stages of drug discovery where the focus is on
the optimisation of efﬁcacy, cytotoxicity and pharmacokinetic
properties. Since mupirocin, the IleRS inhibitor, was ﬁrst intro-duced for clinical use, resistance has developed and in some cases
results in mupirocin treatment failure against S. aureus (Patel et al.,
2009). Parasite drug resistance to aaRS inhibitors has been used in
studies characterising aaRS inhibitors in Plasmodium (Istvan et al.,
2011) and Trypanosoma (Ranade et al., 2013). These studies are
helpful not only in informing mode of action but also useful in
the prediction of development and extent of parasite drug resis-
tance. They enable discussion of relative ﬁtness and ultimately
facilitate the design of inhibitors to which resistance is not so eas-
ily generated.
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